Over a decade of pharma industry experience in China and Asia.
Prior to joining CStone, served as Global VP and Head of Asia Pacific R&D with Sanofi China and led the R&D expansion efforts in the Asia Pacific region, where he oversaw 79 clinical trials with 30 New Drug Approvals in the Asia Pacific region.
Headed an approximately 21,000-patient megatrial (ExTRACT) comparing enoxaparin with unfractionated heparin for acute myocardial infarction, which resulted in the successful global registration of the blockbuster drug Lovenox.
M.D. from Nanjing Medical University in China, Ph.D. in Immunology and Biochemistry from the University of British Columbia in Canada, postdoctoral fellowship at Washington University School of Medicine, certified physician in the U.S. by the Educational Commission for Foreign Medical Graduates.
Over 21 years of experience in biomedical research and clinical development of oncology drugs in the U.S. and China.
Prior to joining CStone, served as the Senior Vice President and Head of Clinical Development at BeiGene Inc., where he led the clinical development of the oncology pipeline and developed the first anti-PD-1 mAb originated in China.
Previously served as Medical Director at Covance Inc.; held research positions at Pfizer Global Research and Development and served as research scientist in the Cancer Genomics Division at Tularik Inc. (acquired by Amgen Inc. in 2004).
Bachelor's degree in medicine from Hubei Medical College, Master's degree in pathophysiology from Nanjing Medical University, Ph.D. in biochemistry and molecular biology with Nobel Laureates Dr. Michael S. Brown and Joseph L. Goldstein at the University of Texas Southwestern Medical Center, postdoctoral fellowship with Dr. Stuart L. Schreiber at Harvard University.
Over 20 years of experience in investment banks and multinational biopharmaceutical companies.
Prior to joining CStone, served as Managing Director and business unit leader of Asia Pacific Healthcare Equity Research at Goldman Sachs (Asia) L.L.C. in Hong Kong, where he led the firm's research efforts for the Chinese and Asian healthcare markets.
Previously served as Head of the China healthcare research team at Citigroup Capital Markets Asia Limited.
Bachelor's degree in medical biophysics from the University of Manitoba, Master's degree in medical biophysics from the University of Toronto and Ontario Cancer Institute, and MBA from Cornell University.
A seasoned business executive with extensive experience in global business development and marketing strategy who has made significant contributions to multiple global oncology brands.
Prior to joining CStone, served as Executive Director and Global Lead of Late Stage Oncology BD&L at Merck & Co., Inc., where he was instrumental in Keytruda's clinical combination partnerships and multiple immuno-oncology deals.
Held various global oncology commercial positions with increasing responsibilities at Novartis Pharmaceuticals, most recently as Executive Director and Head of Life Cycle Strategy. He was previously Senior Manager for global Marketing of Oncology at Eisai Inc.
MBA from Cornell University, Master of Arts, Master of Philosophy and Ph.D. in cellular, molecular and biomedical studies from Columbia University, and Bachelor of Science in biochemistry from Nanjing University.
Over 20 years of experience in oncology research and drug development in biopharmaceutical industry. He has published more than 30 original scientific papers in prestigious journals and is the inventor or co-inventor of multiple international patents including four granted patents.
Prior to joining CStone, served as Director/Senior Principal Scientist of Immuno-Oncology Research at Merck and Co., Inc., where he led and oversaw research projects in relation to immunomodulatory receptor programs with Keytruda as backbone program. He actively participated in evaluating business development opportunities to enrich Merck's pipeline and expand the Keytruda franchise.
Previously served as Associate Director and Principal Scientist of BioSuperiors Department at AstraZeneca/MedImmune LLC and held positions as senior scientist in the Gene Therapy group and principal scientist of Tumor Immunology at Biogen Idec.
Bachelor of Science degree in biochemistry of Graduated from Nankai University, Ph.D. in molecular and cellular biology from Ohio University, postdoctoral training at the Gene Therapy Center of Massachusetts General Hospital, and subsequently served as an instructor of medicine at Harvard Medical School in the U.S.
Over 20 years of experience in global oncology development and scientific research.
A Distinguished Scientist (Executive Director) at Merck (known as MSD outside of U.S. and Canada) in which role he oversaw the early clinical development of a number of novel agents in the immune-oncology pipeline,spanning various mechanisms and action and modalities.
Previously served at Daiichi Sankyo Pharma Development, a Division of Daiichi-Sankyo, Inc., where his last title was Senior Director, Clinical Development.
Served as Clinical Assistant at the US Memorial Sloan-Kettering Cancer Center and a faculty member at the MSKCC affiliated Weill Cornell Medical School.
M.D. and Ph.D. in Biochemistry & Molecular Biology from the University of Southern California , an American Board of Internal Medicine certified medical oncologist.
Prior to joining CStone, served as Executive Director at Simcere Pharmaceutical and General Manager of BioSciKin Bio, a subsidiary of Simcere Pharmaceutical. Previously, served as manager principal scientist at Roche Molecular Systems Inc and senior scientist at BioSpecifics Technologies Corp.
CFDA (NMPA)-appointed expert for the Institute of Executive Development Training.
Ph.D. in medicinal chemistry from China Pharmaceutical University, post-doctorate fellowship at the Department of Pharmacology of Mount Sinai School of Medicine, where he also served as an instructor.